- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05137054
Linvolseltamab (anticuerpo biespecífico anti-BCMA x anti-CD3) más otros tratamientos contra el cáncer para participantes con mieloma múltiple en recaída o refractario (LINKER-MM2)
Estudio de fase 1b de REGN5458 (anticuerpo biespecífico anti-BCMA x anti-CD3) más otros tratamientos contra el cáncer para pacientes con mieloma múltiple en recaída o refractario
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.
In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies).
This study is the first time linvoseltamab will be combined with other cancer therapies.
The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination.
The study is looking at several other research questions, including:
- How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma
- What side effects may happen from taking linvoseltamab together with another cancer treatment
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trials Administrator
- Número de teléfono: 844-734-6643
- Correo electrónico: clinicaltrials@regeneron.com
Ubicaciones de estudio
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitario Vall d'Hebron
-
Barcelona, España, 08036
- Reclutamiento
- Hospital Clinic de Barcelona
-
Barcelona, España, 08908
- Reclutamiento
- Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
-
Madrid, España, 28050
- Reclutamiento
- Hospital Universitario HM Sanchinarro
-
Madrid, España, 28027
- Reclutamiento
- Clinica Universidad de Navarra - Madrid
-
Madrid, España, 28006
- Reclutamiento
- Universitaru Hospital La Princesa
-
Madrid, España, 28041
- Reclutamiento
- University Hospital and Research Institute
-
Madrid, España, 28034
- Reclutamiento
- Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
-
Salamanca, España, 37007
- Reclutamiento
- University Hospital of Salamanca
-
-
A Coruna
-
Santiago de Compostela, A Coruna, España, 15706
- Reclutamiento
- Hospital Clinico Universitario de Santiago
-
-
Barcelona
-
Badalona, Barcelona, España, 08916
- Reclutamiento
- Hospital Germans Trias i Pujol
-
-
Cantabria
-
Santander, Cantabria, España, 39008
- Reclutamiento
- Hospital Universitario Marques de Valdecilla
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, España, 28223
- Reclutamiento
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, España, 31008
- Reclutamiento
- Clinica Universidad de Navarra
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- Reclutamiento
- Scripps Clinic Torrey Pines
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30004
- Reclutamiento
- Winship Cancer Institute of Emory University
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Indiana University Health Simon Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Dana Farber/Harvard Cancer Center
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Reclutamiento
- Karmanos Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Reclutamiento
- Weill Cornell Medicine/New York Presbyterian Hospital
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- New York Presbyterian Hospital Columbia University Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Reclutamiento
- University of North Carolina at Chapel Hill
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Reclutamiento
- Wake Forest University Health Sciences
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- The Ohio State University James Cancer Hospital
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- University of Texas Southwestern
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98108
- Reclutamiento
- VA Puget Sound Health Care System
-
-
-
-
-
Angers, Francia, 49933
- Reclutamiento
- Centre Hospitalier Universitaire Angers
-
Montpellier, Francia, 34295
- Reclutamiento
- CHU Montpellier - Departement D'Hematologie
-
Paris, Francia, 75571
- Reclutamiento
- Saint Antoine Hospital
-
Villejuif, Francia, 94805
- Reclutamiento
- Institut Gustave Roussy
-
-
New Aquitaine
-
Poitiers, New Aquitaine, Francia, 86021
- Reclutamiento
- Centre Hospitalier Universitaire (CHU) de Poitiers
-
-
Nord
-
Lille, Nord, Francia, 59037
- Reclutamiento
- CHU de Lille - Rue Michel Polonovski
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Francia, 44093
- Reclutamiento
- Nantes University Hospital
-
-
Île-de-France Region
-
Créteil, Île-de-France Region, Francia, 94000
- Reclutamiento
- Hospital Henri Mondor
-
Paris, Île-de-France Region, Francia, 75015
- Reclutamiento
- Hopital Necker
-
Paris, Île-de-France Region, Francia, 75010
- Reclutamiento
- Saint Louis Hospital
-
-
-
-
-
Athens, Grecia, 11528
- Reclutamiento
- General Hospital of Athens Alexandra
-
-
Attica
-
Athens, Attica, Grecia, 10676
- Reclutamiento
- Evangelismos General Hospital
-
-
-
-
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Health Care Campus
-
Jerusalem, Israel, 91120
- Reclutamiento
- Hadassah Medical Center
-
-
Central District
-
Ramat Gan, Central District, Israel, 5265601
- Reclutamiento
- Sheba Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
General Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Participants must have measurable disease as defined in the protocol according to IMWG consensus criteria
- Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol
- Life expectancy of at least 6 months
Cohort Specific Inclusion Criteria:
For cohorts 1-6, each participant must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 Proteasome Inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated, as described in the protocol Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 5: Prior treatment with pomalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 6: Prior treatment with isatuximab is allowed if previously tolerated, as described in the protocol
Cohort 7 and 8:
- For participants without measurable disease by biochemical parameters [serum or urine M-protein, or serum involved Free Light Chain (FLC)], presence of at least 1 soft tissue plasmacytoma with a single diameter of ≥2 cm
- RRMM with progressive disease and received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI or triple-class refractory disease (anti-CD38 antibody, IMiD, PI) Cohort 9: Progressive RRMM in participants with triple-class refractory disease (anti-CD38 antibody, IMiD, PI) after at least 3 lines of therapy Cohort 10: Progressive RRMM after at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI
General Key Exclusion Criteria:
- Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
- Participants with known MM brain lesions or meningeal involvement
- Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days prior to first administration of study drug regimen, whichever is shorter
- History of allogeneic and autologous stem cell transplantation, as described in the protocol
- Unless stated otherwise in a specific sub-protocol, prior treatment with a T cell-based immunotherapy directed against B-Cell Maturation Antigen (BCMA) bispecific antibodies and Bispecific T-cell Engagers (BiTEs), and BCMA Chimeric Antigen Receptor (CAR) T cells (Note: BCMA antibody-drug conjugates are not excluded)
- History of progressive multifocal leukoencephalopathy, neurodegenerative condition or Central Nervous System (CNS) movement disorder or participants with a history of seizure within 12 months prior to study enrollment are excluded
- Live or attenuated vaccination within 28 days prior to first study drug regimen administration with a vector that has replicative potential
- Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan
Cohort Specific Exclusion Criteria:
Cohort 2: Dose expansion: Prior treatment with a BCMA-directed CAR T-cell therapy will not be exclusionary if completed at least 12 weeks prior to first study treatment Cohort 3: Known malabsorption syndrome or pre-existing gastrointestinal (GI) condition that may impair absorption of lenalidomide; delivery of lenalidomide via nasogastric tube or gastrostomy tube is not allowed Cohort 4: Peripheral neuropathy grade ≥2 Cohort 5: Known malabsorption syndrome or pre-existing GI conditions that may impair absorption of pomalidomide; delivery of pomalidomide via nasogastric tube or gastrostomy tube is not allowed
Cohort 7:
- Prior treatment with anti-Lymphocyte Activation Gene 3 (LAG-3) agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Programmed cell Death Protein 1 (PD-1) antibodies is permitted, as described in the protocol
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol
- Prior solid organ transplant
- History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies
Cohort 8:
- Prior treatment with anti-PD-1 or anti-PD-L1 agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) antibodies is permitted, as described in the protocol
- Encephalitis or meningitis in the year prior to enrollment
- History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol.
- Prior solid organ transplant
- History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies
Cohort 9:
- Abnormal QT interval corrected by Fridericia's formula (QTcF), as described in the protocol
- Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent
- Ongoing use or anticipated use of food or drugs that are known strong/moderate cytochrome P450 (CYP)3A4 inhibitors, or strong CYP3A inducers within 14 days prior to first dose of nirogacestat
- Known malabsorption syndrome or existing gastrointestinal GI condition that may impair absorption of nirogacestat; delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed
Cohort 10:
- Known or suspected active Epstein-Barr Virus (EBV) infection
- Known history of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
- Prior treatment with cevostamab or another agent with the same target [Fragment crystallizable Receptor-like 5 (FcRH5)]
Dose finding portion: Prior treatment with any BCMA-directed immunotherapy will not be exclusionary, as described in the protocol Dose expansion portion: Prior treatment with any T cell-engaging bispecific antibody directed against BCMA will be exclusionary, as described in the protocol
NOTE: Other protocol defined inclusion/exclusion criteria apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cohort 1: Linvoseltamab + Daratumumab
Linvoseltamab + Daratumumab |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 2: Linvoseltamab + Carfilzomib
Linvoseltamab + Carfilzomib |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 3: Linvoseltamab + Lenalidomide
Linvoseltamab + Lenalidomide |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 4: Linvoseltamab + Bortezomib
Linvoseltamab + Bortezomib |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 5: Linvoseltamab + Pomalidomide
Linvoseltamab + Pomalidomide |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 6: Linvoseltamab + Isatuximab
Linvoseltamab + Isatuximab |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 7: Linvoseltamab + Fianlimab
Linvoseltamab + Fianlimab |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 8: Linvoseltamab + Cemiplimab
Linvoseltamab + Cemiplimab |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 9: Linvoseltamab + Nirogacestat
Linvoseltamab + Nirogacestat |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 10: Linvoseltamab + Cevostamab
Linvoseltamab + Cevostamab |
Administered per the protocol
Otros nombres:
Administered per the protocol
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidencia de eventos adversos graves (SAE)
Periodo de tiempo: Hasta 5 Años
|
Hasta 5 Años
|
|
|
Gravedad de los TEAE
Periodo de tiempo: Hasta 5 Años
|
Hasta 5 Años
|
|
|
Gravedad de los SAE
Periodo de tiempo: Hasta 5 Años
|
Hasta 5 Años
|
|
|
Gravedad de los AESI
Periodo de tiempo: Hasta 5 Años
|
Hasta 5 Años
|
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Periodo de tiempo: Up to 5 Years
|
Up to 5 Years
|
|
|
Incidence of Adverse Events of Special Interest (AESIs)
Periodo de tiempo: Up to 5 Years
|
Up to 5 Years
|
|
|
Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period
Periodo de tiempo: Up to 28 Days
|
Dose finding portion only |
Up to 28 Days
|
|
Incidence of laboratory abnormalities
Periodo de tiempo: Up to 5 Years
|
≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0] |
Up to 5 Years
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Supervivencia general (SG)
Periodo de tiempo: Hasta 5 Años
|
Hasta 5 Años
|
|
Concentraciones de linvoseltamab total en suero a lo largo del tiempo
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
|
Overall Response Rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria
Periodo de tiempo: Up to 5 Years
|
Up to 5 Years
|
|
Duration of Response (DOR) by IMWG criteria
Periodo de tiempo: Up to 5 Years
|
Up to 5 Years
|
|
Progression-Free Survival (PFS) as measured by IMWG criteria
Periodo de tiempo: Up to 5 Years
|
Up to 5 Years
|
|
Rate of Minimal Residual Disease (MRD) negative status by IMWG criteria
Periodo de tiempo: Up to 5 Years
|
Up to 5 Years
|
|
Incidence over time of Anti-Drug Antibodies (ADAs) to linvoseltamab
Periodo de tiempo: Up to 5 Years
|
Up to 5 Years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Trial Management, Regeneron Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Enfermedades hemic y linfáticas
- Mieloma múltiple
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Ácidos carboxílicos
- Piperidinas
- Químicos inorgánicos
- Ácidos borónicos
- Ácidos, no carboxílicos
- Ácidos
- Compuestos de boro
- Pirazinas
- Ftalimidas
- Ácidos ftálicos
- Ácidos, carbocíclicos
- Piperidonas
- Isoindoles
- Lenalidomida
- Bortezomib
- carfilzomib
- pomalidomida
- daratumumab
- cemiplimab
- isacuximab
- nirogacestat
Otros números de identificación del estudio
- R5458-ONC-2012
- 2020-004638-39 (Número EudraCT)
- 2023 (Subvención/contrato del NIH de EE. UU.)
- 2023-506247-42-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Marco de tiempo para compartir IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criterios de acceso compartido de IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .